Report library

Epilepsy KOL Interview – US, West

A US key opinion leader (KOL) discusses the epilepsy treatment landscape, including new market entrant Epidiolex, and provides their perspective on late-phase pipeline anti-epileptic drugs such as Fintepla.

February 18, 2019

Catch Up On CAR-T

$699.00

Sale!

With the approval of the first CAR-T therapies – Novartis’ Kymriah and Gilead/Kite’s Yescarta – what had been the promise of cutting-edge science is now reality.

November 24, 2017

Datamonitor Big Pharma Licensing Trends

This strategy report focuses on Big Pharma Licensing Trends with company analyses, case studies, therapy area analysis, and deal economics.

February 23, 2016

Market Spotlight: Atopic Dermatitis

This Market Spotlight report covers the Atopic Dermatitis market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

August 18, 2020

2018 ASH Pulse Survey

This 9-question pulse survey of 102 hematologic oncologists practicing throughout the United States and Europe.

January 2, 2019

Actelion

Analysis of Actelion’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.

November 1, 2016

Company Analysis : AbbVie

PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2019–29.

July 15, 2020

U.S. Patient Monitoring Devices Market, November 2015

$5,250.00

This report provides a summary of the nearly $2 billion U.S. patient monitoring devices market.

November 2, 2015

Asia-Pacific: Surgical Procedure Volumes

$5,250.00

This report examines the healthcare trends in Asia-Pacific countries (Japan, China, South Korea, India, Thailand, Vietnam, Malaysia and Australia), as well as analyzes and forecasts (toward 2019).

September 1, 2015

Alzheimer’s Disease KOL Interview – US, South

This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.

January 28, 2019

Market Spotlight: Basal Cell Carcinoma

This Market Spotlight report covers the Basal Cell Carcinoma market, comprising key marketed and pipeline drugs, epidemiology, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

September 23, 2021

Market Spotlight: Amyloidosis

This Market Spotlight report covers the Amyloidosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.

November 1, 2021

Market Spotlight: Sjögren’s Syndrome

This Market Spotlight report covers the Sjögren’s syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

September 23, 2021

Big Pharma Outlook 2025

$2,700.00

Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2025.

December 20, 2016

U.S. Markets for Skin Replacements and Substitutes and Active Wound Repair Modulators

$3,750.00

The scope of this report includes tissue-engineered skin replacements and substitutes (i.e., epidermal equivalents, dermal equivalents, and multilayer equivalents) and active wound repair modulators.

February 1, 2013

U.S. Surgical Procedure Volumes

$4,750.00

This report presents the most common surgical procedures performed in the United States (U.S.) as well as an overview of the etiology and epidemiology of selected diseases/disorders, prevailing surgical approaches/techniques, and evolving procedural utilization trends.

November 1, 2015

U.S. Markets for Compression Therapy and Pressure Reduction and Relief Products Used for Wound Management

$3,750.00

The scope of this report includes compression therapy products (e.g., compression bandages, compression stockings, and pneumatic compression devices) and pressure reduction and relief products (e.g., specialty/integrated beds, mattress replacements, and mattress overlays).

April 1, 2013

Immuno-Oncology Deal Trends, 2012–16

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated.

April 19, 2017

Big Pharma Licensing Trends, 2012–16

Between 2012 and 2016, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and annual revenues in excess of $10bn – signed over 1,200 drug-focused deals, growing at a compound annual growth rate of 12%.

March 8, 2017

PCSK9 Inhibitors Pricing Reimbursement and Access

The PCSK9 inhibitors Praluent (alirocumab; Sanofi/Regeneron) and Repatha (evolocumab; Amgen/Astellas) have experienced minimal uptake in the dyslipidemia market since their launches in 2015.

December 21, 2016

PD-1/L1 Immunotherapies: Historical Sales and Market Trend Analysis Report

$7,500.00

Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) has outpaced Merck’s Keytruda (pembrolizumab) primarily
in non-small cell lung cancer (NSCLC) because of its early approval in squamous NSCLC, updated National
Comprehensive Cancer Network (NCCN) guidelines in 2015,

December 22, 2016

2014 October Dermatology Survey

We performed a 5-question survey of 21 dermatologists to gauge usage of drugs and devices for the treatment of common dermatological conditions and for aesthetic procedures.

October 30, 2014

2015 Breast Cancer Pulse #1

This five-question survey of oncologists focuses on treatments for metastatic or locally advanced, HR+/HER2- breast cancer.

May 13, 2015

2014 Community-Acquired Pneumonia Pulse

We performed a 5-question survey of 20 infectious disease (ID) specialists in the U.S. to gauge current prescribing practices for community-acquired pneumonia (CAP) and gauge interest in new drugs/new drug candidates.

December 18, 2014

Rheumatoid Arthritis Payer Interview – Pennsylvania, US

A US payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

August 22, 2019

Market Spotlight: Hereditary Angioedema

This Market Spotlight report covers the Hereditary Angioedema market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

September 30, 2021

Market Spotlight: Hepatitis B

This Market Spotlight report covers the Hepatitis B market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

December 3, 2021

Market Spotlight: Obesity

This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

December 3, 2021

2017 Biomedtracker / Meddevicetracker / Datamonitor Healthcare Post-ESC Report

$4,750.00

The European Society of Cardiology (ESC) Congress 2017 was held in Barcelona, Spain from 26–30 August.

September 14, 2017

Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)

This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

December 2, 2021

Social Media in Pharma

While social media is still relatively new, it has been heralded as one of the most significant changes in the way that people communicate with one another. Despite this, the pharmaceutical industry has been slow to become involved with social media, fearing compliance and regulatory breaches and preferring to stay with the more traditional routes of communication, such as representative visits and emails. However, the growing popularity of social media, combined with a number of positive examples from both within and outside the pharmaceutical industry, has led to an increasing number of pharmaceutical companies looking to grow their social media presence and build on the unique opportunities these platforms offer.

January 27, 2017

Tyvaso for Pulmonary Arterial Hypertension

$89.00

The literature search was undertaken via multiple search engines and strategies with review of cited and associated articles to provide a comprehensive discussion on the topic. Expert opinion: While safe and well tolerated, inhaled treprostinil sodium should be limited, based on available data, to use as add-on therapy for patients with Group I pulmonary hypertension not effectively controlled on oral therapy.

November 29, 2016

CMOs in China and India: Still the Places to be?

$5,000.00

Low-cost and skilled workforces in China and India have positioned both countries as increasingly important manufacturing hubs for pharmaceutical companies, as they seek to contain costs while retaining quality outsourcing partners.

Despite the apparent inevitability of the contract manufacturing organization (CMO) sector’s growth in China and India, a recent wave of scandals has put significant dents in the reputations of both countries as locations for foreign firms to manufacture drugs. Rising costs have also caused some firms to question whether using one of the region’s many CMOs is worth the risk.

November 3, 2016

UK Healthcare System Overview

Reform of the NHS is underway despite widespread controversy and opposition from physicians, and will necessitate a change in the way pharmaceutical companies work with key stakeholders.

November 2, 2016

Big Pharma Outlook 2015

Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies’ sharpened focus on high-performing markets.

September 28, 2016

Orphan Drug Market Outlook to 2017

Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition.

September 28, 2016

Q2 2016 Earnings Previews

Datamonitor Healthcare previews Q2 2016 earnings for companies in the PharmaVitae portfolio. Companies will be continuously added the day before presentations.

September 28, 2016

Rheumatoid Arthritis Payer Interview – UK

A UK payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

August 22, 2019

Big Pharma Licensing Trends, 2014–18

An analysis of the drug-focused licensing deals (out-licensing and in-licensing) made by Big Pharma companies shows an uptick in partnering from 2014 to 2015, followed by a slight decrease in 2016 that has held steady through 2018. Despite that slight decline, the peer set increased deal volume by roughly 15% between the beginning and the end of the five-year period. Total deal values rose even more, roughly 25%.

August 20, 2019

Vaccines Market Access in Emerging Markets

Emerging markets account for approximately 18% of the global vaccines market, which is valued at more than $24bn. However, there are indications that this is an underestimate, and some observers forecast that the overall marketplace will reach $50bn by the mid2020s.

August 29, 2019

Market Spotlight: Idiopathic pulmonary fibrosis (IPF)

This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

November 1, 2021

Market Spotlight: Acute Decompensated Heart Failure (ADHF)

This Market Spotlight report covers the Acute Decompensated Heart Failure (ADHF) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, epidemiology information, licensing and asset acquisition deals, and drug-specific revenues.

December 2, 2021

Market Spotlight: Migraine

This Market Spotlight report covers the migraine market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

August 17, 2020

Digital Pharma: Are We Nearly There?

Digital’s potential to transform every aspect of the pharmaceutical value chain, from discovery to commercial, is widely documented.

August 14, 2018